{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-219421","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2026-05-12T20:10:17+00:00","discovered_at":"2026-05-12T20:11:00.300712+00:00","generated_at":"2026-05-12T21:07:54.133885+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lineage Q1 2026 net loss $4.8M; cash $53.4M; new COR1 program launched","bullets":["Net loss $4.8M ($0.02 basic/$0.03 diluted EPS) vs $4.1M loss in Q1 2025.","Revenue $1.7M (+$0.2M YoY) driven by new WDI collaboration.","Cash & marketable securities $53.4M; expected to fund ops into Q2 2028.","Launched COR1 corneal endothelial cell therapy; second OPC1 spinal cord patient dosed.","First AlloSCOPE 5D milestone achieved; Joachim Fruebis appointed founding SAB member."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-219421","json":"https://secwatch.observer/filing/0001193125-26-219421.json","markdown":"https://secwatch.observer/filing/0001193125-26-219421.md","text":"https://secwatch.observer/filing/0001193125-26-219421.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000119312526219421/0001193125-26-219421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000119312526219421/lctx-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T21:07:54.133885+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2edcb3ed0e5e4230a27278a5f3bfac642134a543","claim":"Lineage Cell Therapeutics, Inc. reported financial results for the quarter ended March 31, 2026.","evidence_excerpt":"On May 12, 2026, Lineage Cell Therapeutics, Inc. issued a press release announcing financial results for the quarter ended March 31, 2026","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526219421/0001193125-26-219421-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}